These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 28466264)

  • 21. Prognostic role of peripheral blood lymphocyte/monocyte ratio at diagnosis in diffuse large B-cell lymphoma: a meta-analysis.
    Lin B; Chen C; Qian Y; Feng J
    Leuk Lymphoma; 2015; 56(9):2563-8. PubMed ID: 25686648
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prediction of Prognosis for Patients with Diffuse Large B-Cell Lymphoma Refractory to or in First Relapse After Initial R-CHOP Therapy: A Single-Institution Study.
    Yamamoto M; Watanabe K; Fukuda T; Miura O
    Anticancer Res; 2017 May; 37(5):2655-2662. PubMed ID: 28476841
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lymphocyte-to-monocyte ratio is associated with prognosis of diffuse large B-cell lymphoma: correlation with CD163 positive M2 type tumor-associated macrophages, not PD-1 positive tumor-infiltrating lymphocytes.
    Wang J; Gao K; Lei W; Dong L; Xuan Q; Feng M; Wang J; Ye X; Jin T; Zhang Z; Zhang Q
    Oncotarget; 2017 Jan; 8(3):5414-5425. PubMed ID: 28036275
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Effect of Lymphocyte/Monocyte Ratio on Clinical Features and Prognosis of Patients with Primary Gastrointestinal Diffuse Large B Cell Lymphoma].
    Xu YX; Zhang YG; Xu CL; Liu NJ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Oct; 24(5):1404-1409. PubMed ID: 27784365
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment response and overall outcome of patients with relapsed and refractory peripheral T-cell lymphoma compared to diffuse large B-cell lymphoma.
    Puig N; Wang L; Seshadri T; al-Farsi K; Keating A; Crump M; Kuruvilla J
    Leuk Lymphoma; 2013 Mar; 54(3):507-13. PubMed ID: 22897731
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lymphopenia predicts preclinical relapse in the routine follow-up of patients with diffuse large B-cell lymphoma.
    Wei X; Wei Y; Huang F; Jing H; Xie M; Hao X; Feng R
    Leuk Lymphoma; 2015 May; 56(5):1261-5. PubMed ID: 25175043
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Critical role of monocytes to support normal B cell and diffuse large B cell lymphoma survival and proliferation.
    Mueller CG; Boix C; Kwan WH; Daussy C; Fournier E; Fridman WH; Molina TJ
    J Leukoc Biol; 2007 Sep; 82(3):567-75. PubMed ID: 17575267
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mediastinal large cell lymphoma: prognostic significance of CT findings at presentation and after treatment.
    Smith D; Shaffer K; Kirn D; Canellos GP; Mauch PM; Shulman LN
    Oncology; 1998; 55(4):284-8. PubMed ID: 9663416
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinicopathologic characteristics and outcomes of transformed diffuse large B-cell lymphoma in hepatitis C virus-infected patients.
    Hosry J; Miranda RN; Samaniego F; Economides MP; Torres HA
    Int J Cancer; 2018 Mar; 142(5):940-948. PubMed ID: 29047108
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety and efficacy of high-dose cyclophosphamide, etoposide and ranimustine regimen followed by autologous peripheral blood stem cell transplant for patients with diffuse large B-cell lymphoma.
    Kobayashi Y; Hatta Y; Sugitani M; Hojo A; Nakagawa M; Kusuda M; Uchino Y; Takahashi H; Kiso S; Hirabayashi Y; Yagi M; Kodaira H; Kurita D; Miura K; Iriyama N; Kobayashi S; Kura Y; Horikoshi A; Sawada U; Takeuchi J; Takei M
    Leuk Lymphoma; 2014 Nov; 55(11):2514-9. PubMed ID: 24491027
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lymphopenia assessed during routine follow-up after immunochemotherapy (R-CHOP) is a risk factor for predicting relapse in patients with diffuse large B-cell lymphoma.
    Porrata LF; Rsitow K; Inwards DJ; Ansell SM; Micallef IN; Johnston PB; Habermann TM; Witzig TE; Colgan JP; Nowakowski GS; Thompson CA; Markovic SN
    Leukemia; 2010 Jul; 24(7):1343-9. PubMed ID: 20485372
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The lymphocyte to monocyte ratio improves the IPI-risk definition of diffuse large B-cell lymphoma when rituximab is added to chemotherapy.
    Rambaldi A; Boschini C; Gritti G; Delaini F; Oldani E; Rossi A; Barbui AM; Caracciolo D; Ladetto M; Gueli A; De Crescenzo A; Passera R; Devizzi L; Patti C; Gianni AM; Tarella C
    Am J Hematol; 2013 Dec; 88(12):1062-7. PubMed ID: 23940056
    [TBL] [Abstract][Full Text] [Related]  

  • 33. An inflammation-based cumulative prognostic score system in patients with diffuse large B cell lymphoma in rituximab era.
    Sun F; Zhu J; Lu S; Zhen Z; Wang J; Huang J; Ding Z; Zeng M; Sun X
    BMC Cancer; 2018 Jan; 18(1):5. PubMed ID: 29291712
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The International Prognostic Index assessed at relapse predicts outcomes of autologous transplantation for diffuse large-cell non-Hodgkin's lymphoma in second complete or partial remission.
    Lerner RE; Thomas W; Defor TE; Weisdorf DJ; Burns LJ
    Biol Blood Marrow Transplant; 2007 Apr; 13(4):486-92. PubMed ID: 17382255
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Diffuse large B-cell lymphoma: the challenge of relapse after an autologous stem cell transplant.
    Robinson SP
    Bone Marrow Transplant; 2017 Feb; 52(2):199-200. PubMed ID: 27869811
    [No Abstract]   [Full Text] [Related]  

  • 36. Prognostic value of lymphocyte-to-monocyte ratio and neutrophil-to-lymphocyte ratio in follicular lymphoma: a retrospective cohort study.
    Lee SF; Luque-Fernandez MA
    BMJ Open; 2017 Nov; 7(11):e017904. PubMed ID: 29101140
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Highly elevated serum lactate dehydrogenase is associated with central nervous system relapse in patients with diffuse large B-cell lymphoma: Results of a multicenter prospective cohort study.
    Kim SJ; Hong JS; Chang MH; Kim JA; Kwak JY; Kim JS; Yoon DH; Lee WS; Do YR; Kang HJ; Eom HS; Park Y; Won JH; Mun YC; Kim HJ; Kwon JH; Kong JH; Oh SY; Lee S; Bae SH; Yang DH; Jun HJ; Kim YS; Yun HJ; Lee SI; Kim MK; Park EK; Kim WS; Suh C
    Oncotarget; 2016 Nov; 7(44):72033-72043. PubMed ID: 27713132
    [TBL] [Abstract][Full Text] [Related]  

  • 38. New-onset lymphopenia assessed during routine follow-up is a risk factor for relapse postautologous peripheral blood hematopoietic stem cell transplantation in patients with diffuse large B-cell lymphoma.
    Porrata LF; Inwards DJ; Ansell SM; Micallef IN; Johnston PB; Hogan WJ; Markovic SN
    Biol Blood Marrow Transplant; 2010 Mar; 16(3):376-83. PubMed ID: 19883776
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Heart as the site of first relapse in diffuse large B-cell lymphoma.
    Singhal M; Raina V; Medhi K; Gupta C; Reddy RM
    Indian J Cancer; 2010; 47(2):220-2. PubMed ID: 20448391
    [No Abstract]   [Full Text] [Related]  

  • 40. Minimal residual disease detection by flow cytometry and PARR in lymph node, peripheral blood and bone marrow, following treatment of dogs with diffuse large B-cell lymphoma.
    Aresu L; Aricò A; Ferraresso S; Martini V; Comazzi S; Riondato F; Giantin M; Dacasto M; Guadagnin E; Frayssinet P; Rouquet N; Drigo M; Marconato L
    Vet J; 2014 May; 200(2):318-24. PubMed ID: 24698669
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.